REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President of Foamix Pharmaceuticals, will provide a corporate overview and business update at the Cowen & Company 35th Annual Health Care Conference.
|Title:||Cowen & Company 35th Annual Health Care Conference|
|Date:||Monday, March 2, 2015|
|Location:||The Boston Marriott Copley Place, Boston, MA|
About Foamix Pharmaceuticals
We are a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for the treatment of acne and other skin conditions. Our lead product candidate, FMX101 for moderate-to-severe acne is a topical foam formulation of the antibiotic minocycline. We also have early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: U.S. Investor Relations Andrew McDonald LifeSci Advisors, LLC 646-597-6987 email@example.com